InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,864.67
(
0.40%
)
US TECH 100
19,783.20
(
0.68%
)
Dow Jones
43,275.91
(
0.09%
)
Brent Oil
72.90
(
-0.03%
)
Bitcoin
69,137.87
(
0.20%
)
Post# of 253408
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120588
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 195851

Monday, 01/11/2016 3:27:52 PM

Monday, January 11, 2016 3:27:52 PM

Post# of 253408
EXAS -13% on soft 4Q15/unchanged 2016 guidance:

http://finance.yahoo.com/news/exact-sciences-announces-preliminary-fourth-110000111.html

Based on Exact Sciences' current forecasts, the company is reaffirming its guidance of completing more than 240,000 Cologuard tests and generating between $90-100 million in revenue in 2016. This represents a greater than 130-percent year-over-year increase in the number of Cologuard tests completed.

Some investors apparently expected EXAS to raise 2016 guidance.

The share price is down 79%(!) from its Jun 2015 high.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up